Grifols SA engages in the production of plasma derivatives. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Follow-Up Questions
Grifols SA のCEOは誰ですか？
Mr. Jose Ignacio Abia は Grifols SA の Chief Executive Officer で、2024 から在籍しています。
GIFOF の株価パフォーマンスは？
GIFOF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Grifols SA の主な事業テーマや業界は？
Grifols SA は Biotechnology 業界、セクターは Health Care に属しています。
